Omnicell (NASDAQ:OMCL) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Omnicell (NASDAQ:OMCL) from an equal weight rating to an overweight rating in a research note released on Wednesday, Marketbeat.com reports. Wells Fargo & Company currently has $35.00 price target on the stock, up from their prior price target of $31.00.

Other analysts have also issued reports about the company. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, May 3rd. Benchmark lowered their price target on Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. lowered their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $46.50.

Omnicell Trading Down 0.4%

Omnicell stock opened at $27.96 on Wednesday. The stock has a 50-day moving average of $31.41 and a two-hundred day moving average of $39.55. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell has a one year low of $22.66 and a one year high of $55.75. The stock has a market cap of $1.31 billion, a PE ratio of 103.56, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm had revenue of $269.67 million during the quarter, compared to analysts’ expectations of $260.18 million. During the same period last year, the business posted $0.03 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. On average, research analysts anticipate that Omnicell will post 1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Shaker Investments LLC OH acquired a new position in Omnicell during the 4th quarter worth $550,000. Empowered Funds LLC acquired a new stake in shares of Omnicell in the 4th quarter valued at approximately $388,000. Exchange Traded Concepts LLC increased its stake in Omnicell by 6.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company’s stock valued at $14,232,000 after purchasing an additional 20,031 shares in the last quarter. Jane Street Group LLC increased its stake in Omnicell by 7.4% in the 4th quarter. Jane Street Group LLC now owns 54,282 shares of the company’s stock valued at $2,417,000 after purchasing an additional 3,725 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in Omnicell by 56.5% during the fourth quarter. SG Americas Securities LLC now owns 39,359 shares of the company’s stock worth $1,752,000 after buying an additional 14,202 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.